6B. Neurologic Disorders Flashcards
Parkinson’s Disease
► Degenerative CNS disorder characterized by ____ deficiency
► Affects approximately 500,000 people
► 1 % over age 50 have the disease
►2.5 % over the age of 70 have the disease
► ____x increase in frequency is predicted in the next 50 years
dopamine
3-4
Etiology / Pathophysiology
► Primary
– Degeneration of dopaminergic neurons of the
____
► Secondary
– Loss of or interference with the action of ____ 20 to other CNS diseases
► Associated factors – \_\_\_\_ mutation – Stroke – \_\_\_\_ tumor – Head injury – Exposure to \_\_\_\_
substantia nigra dopamine genetic brain chemicals
Signs / Symptoms
►Resting tremors
– ____
– Seen in extremities at ____ – “Pill – rolling“
►Muscle rigidity
– ____ arm swing with walking
– ____ posture
– ____ instability
►Pain
►\_\_\_\_ dysfunction ►Slow movements ►Facial \_\_\_\_ ►“Restlessness” ►Impairment of \_\_\_\_ and concentration ►Mood disturbances ►\_\_\_\_
rhythmic rest decreased bent gait
bladder/bowel
impassiveness
memory
dementia
Diagnosis ►Physical signs and symptoms ►No reliable \_\_\_\_ or biochemical markers for PD ►Neuroimaging – Evaluate \_\_\_\_ production – Rule out other CNS pathology ►Positive clinical response to \_\_\_\_
Rest means more acitivity, ____ is less activity.
This is substantia nigra section of the brain translating to dopramine activity
histological
dopamine
carbidopa/levodopa
blue
Medical Management ►Mainstay of treatment has been replacement of \_\_\_\_ ►Sinemet® (Carbidopa / Levodopa) – Levodopa (L-dopa) ►Metabolic precursor of \_\_\_\_ ►Crosses \_\_\_\_
– Carbidopa
►Inhibits ____ of peripheral levodopa
– May induce ____
– Medication must be ____ carefully to diminish dyskinesia
dopamine
dopamine
BBB
decarboxylation
dyskinesia
titrated
Oral considerations ►Oral motor and sensory impairment ►\_\_\_\_ ►Xerostomia ►\_\_\_\_ ►Burning mouth syndrome
dysphagia
candidiasis
►Preventive strategies ►Consider patient’s physical and cognitive deficiencies – Electric toothbrushes – Modification of oral hygiene aids – \_\_\_\_ rinses – Topical fluoride – \_\_\_\_
►Therapeutic strategies – Venue for dental treatment – Orthostatic \_\_\_\_ – Facial / oral muscle tremor – Increased salivation – Basic vs. complex dental treatment – Choice of dental restorative \_\_\_\_ – Drug interactions
chlorhexidine
sialogogues
hypotension
materials
Alzheimer’s Disease
►Neurodegenerative disease characterized by ____
►Gradual ____ in cognitive processes
►May lead to total ____ disability
dementia
decline
mental and physical
Epidemiology (AD)
►> 5 million people in the U.S. affected by dementia / AD
– 18.5 million cases in the U.S. by the year 2050
►Incidence
– 11% over age 65
– 50% over age 85
►____ are at greater risk than men for development of AD
►Genetic predisposition
– Early onset AD
►More ____
►Progresses more ____
women
severe
rapidly
Etiology (AD)
►Primary pathophysiologic mechanism of AD – Excessive \_\_\_\_ deposition – \_\_\_\_ plaques – \_\_\_\_ tangles
►Loss of ____ input into the cortex
►Age ►\_\_\_\_ sex ►Prior head injury ►Family history ►\_\_\_\_ genotype ►\_\_\_\_ mutation ►Trisomy \_\_\_\_
beta amyloid
neuritic
neurofibrillary
cholinergic
female
ApoE4
SORL1
21
AD Brain
Macro and both micro changes in brain. This picture is for macro changes:
• Decrease in amount of brain tissue in areas
• ____ of ventricles
• ____ of sulcus
• Pronounced ____ in language and memory cortices.
widening
deepening
decrease
Signs / Symptoms (AD) ►Gradual deterioration – \_\_\_\_ – Orientation – \_\_\_\_ stability – Language capacity – \_\_\_\_ thinking – Motor skills – Self \_\_\_\_
memory
emotional
abstract
care
Diagnosis (AD)
► Dementia established by clinical examination and documented with testing (MMSE)
► Deficits in two or more areas of ____
► Progressive worsening of memory and other cognitive functions
► No disturbance of ____
► Onset between ages 40 and 90
► Absence of systemic disorders or other brain diseases that could account for the progressive memory and cognitive changes
cognition
consciousness
►Three stages of disease – Progress though stages variable ►\_\_\_\_ AD ►Mild cognitive impairment (MCI) – \_\_\_\_ loss (most prominent feature) – Time disorientation – \_\_\_\_ errors – Notable decline in personal appearance / hygiene
preclinical
memory
judgement
►Dementia due to AD – Rapid decline in \_\_\_\_ capacity – Inability to ►Recognize \_\_\_\_ ►Understand speech ►Recognize \_\_\_\_ objects
►Dementia due to AD – Advanced disease ►\_\_\_\_ ►Unable to walk ►Body \_\_\_\_ ►Seizures ►Hyperorality ►\_\_\_\_ behavior
• Death from ____, secondary infection, or ____ disease
intellectual
self
familiar
disoriented
wasting
aggressive
malnutrition
Medical Management (AD)
►No definitive cure
►Use of acetylcholinesterase
inhibitors
– ____ (Aricept®)
►Use of NMDA receptor antagonist
►____ (Namenda®)
►Improve cognition – NSAID’s – Antioxidants (\_\_\_\_ – \_\_\_\_ biloba ►\_\_\_\_ ►Symptom-specific medication
donepezil memnatine vitamin E ginkgo antipsychotics
Dental Management
► Dental treatment planning, oral care, and behavioral management for persons with AD must be designed with consideration of the severity of the disease and must involve family members
►AD patients at increased risk for: – Coronal and root \_\_\_\_ – Periodontal diseases – \_\_\_\_ disorders – Orofacial pain
caries
TMJ
AD
►Aggressive preventive measures – Topical \_\_\_\_ – Chlorhexidine – Frequent recall visits ►Maintain updated medical and medication records ►Dental appointments / instructions may be \_\_\_\_ ►Dentures are frequently \_\_\_\_ / lost
fluoride
forgotten
broken